NMTR
Price:
$0.0722
Market Cap:
$1.04M
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prev...[Read more]
Industry
Biotechnology
IPO Date
2016-07-11
Stock Exchange
NASDAQ
Ticker
NMTR
According to 9 Meters Biopharma, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is -725468.00. This represents a change of -102.12% compared to the average of 34.28M of the last 4 quarters.
The mean historical Enterprise Value of 9 Meters Biopharma, Inc. over the last ten years is 49.15M. The current -725468.00 Enterprise Value has changed -247.59% with respect to the historical average. Over the past ten years (40 quarters), NMTR's Enterprise Value was at its highest in in the June 2018 quarter at 599.12M. The Enterprise Value was at its lowest in in the December 2021 quarter at -46825347.00.
Average
49.15M
Median
24.04M
Minimum
8.24M
Maximum
191.11M
Discovering the peaks and valleys of 9 Meters Biopharma, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 790.86%
Maximum Annual Enterprise Value = 191.11M
Minimum Annual Increase = -87.75%
Minimum Annual Enterprise Value = 8.24M
Year | Enterprise Value | Change |
---|---|---|
2022 | 23.41M | -87.75% |
2021 | 191.11M | 259.72% |
2020 | 53.13M | 208.90% |
2019 | 17.20M | -69.65% |
2018 | 56.67M | -22.85% |
2017 | 73.45M | 790.86% |
2016 | 8.24M | -64.97% |
2015 | 23.54M | -4.09% |
2014 | 24.54M | 21.24% |
The current Enterprise Value of 9 Meters Biopharma, Inc. (NMTR) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
89.21M
5-year avg
68.30M
10-year avg
49.15M
9 Meters Biopharma, Inc.’s Enterprise Value is less than Mereo BioPharma Group plc (582.99M), less than Acumen Pharmaceuticals, Inc. (93.64M), less than Day One Biopharmaceuticals, Inc. (1.01B), less than Inozyme Pharma, Inc. (343.89M), greater than Galera Therapeutics, Inc. (-5475585.00), less than Aileron Therapeutics, Inc. (38.72M), less than Artelo Biosciences, Inc. (1.27M), greater than Histogen Inc. (-3633213.00), less than Curis, Inc. (61.70M), greater than Timber Pharmaceuticals, Inc. (-798315.00), less than Kineta, Inc. (7.82M), less than Candel Therapeutics, Inc. (194.11M), less than MiNK Therapeutics, Inc. (26.26M), less than Forte Biosciences, Inc. (1.54M), greater than AlloVir, Inc. (-7576067.00), less than ZIVO Bioscience, Inc. (37.60M), less than RenovoRx, Inc. (12.72M), less than Tempest Therapeutics, Inc. (20.39M), less than Ikena Oncology, Inc. (46.38M), less than Catalyst Biosciences, Inc. (19.42M), less than MEI Pharma, Inc. (29.95M), greater than Magenta Therapeutics, Inc. (-114170976.00), less than Kezar Life Sciences, Inc. (30.16M), less than Vincerx Pharma, Inc. (15.98M), greater than Avenue Therapeutics, Inc. (-868251.00),
Company | Enterprise Value | Market cap |
---|---|---|
582.99M | $664.26M | |
93.64M | $133.38M | |
1.01B | $1.25B | |
343.89M | $312.42M | |
-5475585.00 | $4.08M | |
38.72M | $60.66M | |
1.27M | $3.87M | |
-3633213.00 | $939.79K | |
61.70M | $29.78M | |
-798315.00 | $1.18M | |
7.82M | $8.08M | |
194.11M | $197.00M | |
26.26M | $31.17M | |
1.54M | $11.11M | |
-7576067.00 | $88.16M | |
37.60M | $37.03M | |
12.72M | $24.47M | |
20.39M | $31.26M | |
46.38M | $81.56M | |
19.42M | $19.42M | |
29.95M | $20.65M | |
-114170976.00 | $42.44M | |
30.16M | $40.82M | |
15.98M | $22.05M | |
-868251.00 | $4.05M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like 9 Meters Biopharma, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like 9 Meters Biopharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is 9 Meters Biopharma, Inc.'s Enterprise Value?
What is the highest Enterprise Value for 9 Meters Biopharma, Inc. (NMTR)?
What is the 3-year average Enterprise Value for 9 Meters Biopharma, Inc. (NMTR)?
What is the 5-year average Enterprise Value for 9 Meters Biopharma, Inc. (NMTR)?
How does the current Enterprise Value for 9 Meters Biopharma, Inc. (NMTR) compare to its historical average?